Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane Meeting Abstract
| Authors: | O'Shaughnessy, J.; Schwartzberg, L.; Piccart, M.; Rugo, H. S.; Yardley, D. A.; Cortes, J.; Untch, M.; Harbeck, N.; Wright, G. S.; Bondarenko, I.; Glaspy, J.; Nowecki, Z.; Kayali, F.; Chan, A.; Levy, C.; Liu, M. C.; Kim, S. B.; Lemieux, J.; Manikhas, A.; Tolaney, S.; Lim, E.; Gombos, A.; Stradella, A.; Pegram, M.; Fasching, P.; Mangel, L.; Semiglazov, V.; Dieras, V.; Gianni, L.; Danso, M. A.; Vacirca, J.; Kroll, S.; O'Connell, J.; Tang, K.; Wei, T.; Seidman, A. |
| Abstract Title: | Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane |
| Meeting Title: | 43rd Annual San Antonio Breast Cancer Symposium (2020 SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 81 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2020 Dec 8-11 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2021-02-01 |
| Language: | English |
| ACCESSION: | WOS:000618737700023 |
| PROVIDER: | wos |
| DOI: | 10.1158/1538-7445.SABCS20-GS4-01 |
| Notes: | Meeting Abstract: GS4-01 -- This symposium was held virtually due to COVID-19 -- Source: Wos |
